지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
The pharmacotherapy of depression has reduced morbidity and improved outcome for many depressive patients. A wide range of classical and new antidepressants are available for their treatment. However, 30-40% of all patients do not respond sufficiently to the initial treatment and present adverse effects. Pharmacogenetics studies the genetic basis of an individual's ability to respond to pharmacotherapy. Recently, some reports on serotonin transporter gene polymorphisms and their influence on the response to antidepressive therapy provide an interesting diagnostic tool in assessing the chances of response to antidepressants. We also investigated the relationship between serotonin transprter polymorphisms(5-HTTLPR) and the long-term effect of the antidepressant treatment. 128 depressive patients were enrolled into 2nd year study. The therapeutic response of each subset was not different at 8th, 16th week, but the subset with homozygote(l/l) of long variant showed a better therapeutic response to antidepressant than the heterozygote(l/s) of long and short variant, which showed a better therapeutic response than the subset with homozygote (s/s) of short variant at 1st year and 2nd year after the antidepressant treatment. This result shows that the serotonin transporter polymorphisms may be related to the long-term effect of antidepressant treatment. The potential for pharmacogenomics, the use of genetic information to guide pharmacotherapy and improve outcome by providing individualized treatment decisions, has gained increasing attention. pharmacogenomics will contribute to individualize drug choice by using genotype to predict positive clinical outcomes, adverse reactions, and levels of drug metabolism. Personalized medicine, the use of marker-assisted diagnosis and targeted therapies derived from an individual molecular profile, will impact the antidepressant therapy and this approach will replace the traditional trial-and-error practice of medicine.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
한국인 우울 장애 환자에서 5-HTTLPR과 항우울제의 장기 치료 반응
생물정신의학
2002 .01
-
Pharmacogenomic Study of Patients with Depression
Clinical Psychopharmacology and Neuroscience
2008 .01
-
우울증과 항우울작용에 관한 p11(S100A10)의 역할
생물정신의학
2016 .01
-
Antidepressant Prescribing Patterns in Korea: Results from the Clinical Research Center for Depression Study
PSYCHIATRY INVESTIGATION
2011 .01
-
The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology
PSYCHIATRY INVESTIGATION
2018 .01
-
새로운 우울증 치료 약물
생물정신의학
2016 .01
-
Effects of BDNF Polymorphisms on Antidepressant Action
PSYCHIATRY INVESTIGATION
2010 .01
-
No Effect of Serotoninergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression
PSYCHIATRY INVESTIGATION
2013 .01
-
Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response
PSYCHIATRY INVESTIGATION
2008 .01
-
근거중심 한국형 우울증 약물학적 치료지침, 개정판(II) : 항우울제의 위약대비 효과, 항우울제간 효과차이 및 효과판정의 적정시점
신경정신의학
2013 .01
-
항우울제와 관련된 사망사례분석 - 2010년 수도권을 중심으로 -
약학회지
2013 .01
-
우울증 치료제들의 작용기전에 대한 신경생물학적 소견
생물치료정신의학
1995 .12
-
한국인들의 항우울제에 대한 인식 및 태도에 관한 연구
한국임상약학회지
2012 .01
-
Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
Clinical Psychopharmacology and Neuroscience
2020 .01
-
근거중심 한국형 우울증 약물학적 치료지침, 개정판(III) : 항우울제의 증량, 교체, 병합 및 강화요법
신경정신의학
2013 .01
-
Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
Clinical Psychopharmacology and Neuroscience
2015 .01
-
항우울제와 자살
생물정신의학
2006 .01
-
주요우울증에서 치료반응을 예측할 수 있는가?
생물정신의학
2004 .01
-
Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting
PSYCHIATRY INVESTIGATION
2010 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0